Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 6/20 | 0.78 |
| ▸ | P2RX2 | Q9UBL9 | 6/20 | 0.78 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.78 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.77 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.72 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.72 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.72 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.72 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.72 |
| ▸ | SRC | P12931 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | NT5E | P21589 | 1/20 | 0.70 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.69 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.67 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.67 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.67 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.67 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.65 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14178286 | 0.92 | P2RX3 (0.79) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL14929510 | 0.92 | P2RX3 (0.79) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL624619 | 0.92 | P2RX3 (0.79) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL29353873 | 0.92 | P2RX3 (0.79) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL3502130 | 0.92 | P2RX3 (0.79) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL14946389 | 0.92 | P2RX3 (0.79) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL31029196 | 0.91 | P2RX3 (0.86) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL31396265 | 0.91 | P2RX3 (0.77) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL29799399 | 0.89 | P2RY1 (0.75) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL23078457 | 0.88 | P2RX3 (0.75) | P2RX3P2RX2P2RX4GPR17P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629320-B2 | Nucleoside derivatives for treating hepatitis C virus infection | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629320-B2 | Nucleoside derivatives for treating hepatitis C virus infection | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080249060-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080249060-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-7425547-B2 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425547-B2 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20040147464-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249060-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | HAVCR2, PNP, NTPCR | P2RX3 1234/4885P2RX2 2406/4885P2RX4 2005/4885 |
| US-20040147464-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | P2RX3 1234/4885P2RX2 2406/4885P2RX4 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.